Improving outcomes for patients with glioblastoma by combining chemo-radiation with inhibitors of DNA repair
Professor Anthony Chalmers
Institute of Cancer Sciences, University of Glasgow
Anthony Chalmers is Chair of Clinical Oncology at the University of Glasgow. His clinical practice is based at the Beatson West of Scotland Cancer Centre and is devoted to the treatment of patients with brain tumours. The objective of his research programme is to improve outcomes for patients with brain tumours by enhancing the response of these tumours to radiotherapy and chemotherapy. There are three key elements of the research programme: (1) developing new laboratory models of glioblastoma that more closely resemble the tumours found in patients, (2) laboratory testing of new drugs in combination with radiotherapy and chemotherapy, and (3) developing and leading clinical trials of these new treatments.
During his Clinical Oncology training he developed an interest in radiobiology which led to a PhD at the Gray Cancer Institute investigating the effects of combining radiotherapy with PARP inhibitors. After completing his specialist training at the Royal Marsden Hospital, he was awarded a Medical Research Council Clinician Scientist Fellowship and set up a research laboratory at the University of Sussex. The laboratory studies on PARP inhibitors have led to a programme of clinical trials that will test the PARP inhibitor olaparib in patients with glioblastoma. The first study has been funded by Cancer Research UK and opened to recruitment in August 2011. In 2009 he successfully applied for a Medical Research Council Senior Clinical Fellowship and in September 2010 was recruited to his current position at the University of Glasgow.